Copanlisib Synergies With Conventional and Targeted Agents Including Venetoclax in Preclinical Models of B- And T-Cell Lymphomas

Hematological Oncology - United Kingdom
doi 10.1002/hon.127_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Venetoclax Synergizes With Radiotherapy for Treatment of B-Cell Lymphomas

Cancer Research
Cancer ResearchOncology
2017English

Combinatorial Screening of the Pi3k Inhibitor Copanlisib in T Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

The Evolving Role of Targeted Biological Agents in the Management of Indolent B-Cell Lymphomas

Therapeutic Advances in Hematology
Hematology
2017English

In Vitro Demonstration of Synergism With Pixantrone Combined With Targeted Agents in Lymphomas

British Journal of Haematology
Hematology
2018English

Outcomes of Patients With Large B‐Cell Lymphomas and Progressive Disease Following CD19‐Specific CAR T‐Cell Therapy

American Journal of Hematology
Hematology
2019English

Copanlisib and Volasertib Overcome Ibrutinib-Venetoclax Resistance via Targeting Pi3k-Akt Signaling and G2/M Cell Cycle Transition in Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Cell Cycle Deregulation in B-Cell Lymphomas

Blood
BiochemistryImmunologyCell BiologyHematology
2003English

The BTK Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents

Haematologica
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy